Adenoid Cystic Carcinoma Research Foundation

08/25/2026

The Summer 2026 ACCRF Research Update is now available! This edition features Patient Champion Amanda Kedaigle; an in-depth look at ACC molecular subtypes; our upcoming webinar and patient meeting; and the latest updates in clinical trials and research publications. Don't forget to sign up for our newsletter to stay informed on all the latest in ACC research and news!

Email from ACCRF Honoring Mandy Kedaigle, LA Patient Meeting, Latest Webinar, and More! ACCRF Research Update - August 2026 Dear Friends, As the summer draws to a close and I mark my first six months

08/17/2026

ACCRF grantee Dr. Renata Ferrarotto of MD Anderson Cancer Center discusses the biological rationale for and interim findings from a phase 1 study of Emi-Le in patients with aggressive ACC.

Renata Ferrarotto, MD, discusses the biologic rationale for and interim findings from a phase 1 study of Emi-Le in patients with aggressive ACC.

08/07/2026

A phase 2 trial testing Becotatug Vedotin (EGFR ADC) and Stereotactic body radiation therapy (SBRT) opens in ACC patients with recurrent or metastatic disease.

07/31/2026

ACCRF grantees Drs. Patrick Ha and Hyunseok Kang report that in preclinical ACC models, the AXL-targeted antibody drug conjugate mipasetamab uzoptirine (ADCT-601) demonstrates strong anti-tumor activity, including tumor shrinkage and, in some cases, complere eradication. These findings support continued clinical development of AXL-targeted therapies for ACC.

Adenoid cystic carcinoma (ACC) is a rare salivary gland malignancy with no FDA-approved systemic therapies and limited benefit from conventional treatments. Proteogenomic profiling has revealed consistent overexpression of AXL, providing a compelling rationale to pursue AXL as a novel therapeutic ta...

07/14/2026

ACCRF grantee Dr. Paolo Bossi explores the current state of curative treatments, and their role in achieving locoregional control and disease-free survival.

Adenoid cystic carcinoma (AdCC) of the salivary glands is a rare malignancy characterized by a poor outcome at long term follow-up. While the locoregional treatment of the primary tumor is mainly based on surgery and radiation therapy, the disease typically recurs at distance, for which curative opt...

06/24/2026

Exactly one year ago this month, we saw the first reports from clinical trials that delivered some of the best results ever recorded in ACC patients. At this year’s American Society of Clinical Oncology (ASCO) meeting, new updates from these clinical trials were shared affirming the initial strong response rates for these treatments. This incredibly promising data reinforces our hope that we have new, effective treatments in the clinical trial pipeline that may gain FDA approval.

The results are no fluke.

The clinical trials highlighted this year–and the many that came before and are still to come–are the result of two decades of concerted effort from patients, scientists, physicians, and the many dedicated ACC community members like you. Your support fuels the innovation that has brought us to this moment and will propel researchers closer to new treatments for ACC.

When you give to ACCRF, you make a tangible difference in the lives of patients. Please give today to safeguard the future of ACC research and treatment.

accrf.org/donate

06/09/2026

The Spring 2026 ACCRF Research Update is now available! This edition features highlights and new clinical trial data from this year's ASCO annual meeting; a look at Patient Meetings held this year; the most recent Patient Webinar; and the latest updates in clinical trials and research publications. Don't forget to sign up for our newsletter to stay informed on all the latest in ACC research and news!

Email from ACCRF ASCO Highlights, Patient Meetings, the Latest Webinar, and More! ACCRF Research Update - June 2026 For 20 years, ACCRF has been building a global network dedicated to advancing resear

05/21/2026

There's still time to register for our upcoming Patient Meeting in Chicago!

Please join us Saturday, May 30 from 10am-12pm CT in Chicago, IL, USA for a day of community, connection, and education at the the 2026 Midwest ACCRF Patient Meeting.

This unique, in-person event provides a forum for ACC patients to meet, discuss their journeys, and hear about the latest in ACC research and treatment options.

PLEASE NOTE: This is an in-person only event and will not have a virtual option.

To learn more and register for the event, follow the link below. We hope to see you there!

https://lp.constantcontactpages.com/ev/reg/654umy6

05/12/2026

JUST ANNOUNCED: The FDA has granted Breakthrough Therapy Designation to Servier Pharmaceutical’s Emi-Le—a B7-H4-targeting antibody drug conjugate—for ACC patients with solid histology or more aggressive forms of the disease. Breakthrough Therapy Designation is granted when early clinical data suggest a drug may provide substantial clinical benefit for a serious disease, particularly when treatment options are limited. The designation allows for closer collaboration with the FDA and may help accelerate the development and review process for the therapy.

Early results from the Emi-Le clinical trial presented in June of 2025 showed that 56% of ACC patients with aggressive disease had their tumors shrink by 30% or more.

https://tinyurl.com/mvst7hdj

To learn more about Emi-Le and other clinical trials for ACC patients, visit ACCRF's Open Studies webpage and our feature on Emi-Le from 2025 (both linked below). Stay up to date on the latest in ACC news and research by joining our mailing list and following us on social media.

https://linktr.ee/accrf
https://accrf.org/new-b7-h4-adc/
https://accrf.org/treatments/clinical-trials/open-studies/

Emi-Le is a potentially innovative and differentiated antibody drug conjugate (ADC) directed against B7-H4, a well-characterized target in certain cancers including ACC Emi-Le is currently under...